Advertisement

November 10, 2016 - Supplement   (View All Issues)

    Introduction

    As expensive cancer biologics move off patent, biosimilar products are coming on board. These are highly similar versions of licensed biologics that demonstrate near-fingerprint identity to their reference products in terms of structure and potency. Biosimilars...

    Biosimilars in Oncology

    In a Roundtable Discussion held during the 2015 American Society of Hematology (ASH) Annual Meeting, several experts addressed questions related to biosimilar products and gauged the potential impact of these drugs on oncology care. These experts included Robert Rifkin, MD, FACP, Medical Director...

Advertisement



Advertisement

click me